文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

D2EFT研究96周最终结果:多替拉韦联合达芦那韦对比标准方案在NNRTI失败后的疗效

A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

D2EFT是一项在14个中低收入国家开展的多中心、随机、开放标签IIIB/IV期试验,纳入828例一线NNRTI方案失败的HIV-1感染者,比较三种二线方案的96周病毒学抑制情况。结果显示DTG+DRV/r和DTG+TDF/XTC均优于DRV/r+2NRTIs,但DTG+TDF/XTC组出现多替拉韦耐药。

要点

  • 96周病毒学抑制率:DTG+DRV/r为85.7%,DTG+TDF/XTC为81.6%,DRV/r+2NRTIs为76.1%。
  • DTG+DRV/r和DTG+TDF/XTC相比DRV/r+2NRTIs的抑制率差异分别为9.6%和9.0%。
  • 多替拉韦耐药仅见于DTG+TDF/XTC组(13%的病毒学失败者),需持续监测。

核心结论

  • 一线NNRTI方案失败后,含多替拉韦的二线方案在96周时病毒学抑制优于DRV/r+2NRTIs。

研究设计与样本

  • 多中心、随机、开放标签IIIB/IV期试验,在14个中低收入国家开展。
  • 828例一线NNRTI方案失败的HIV-1感染者被随机分组,826例纳入分析。

主要发现

  • 96周HIV RNA<50 copies/mL比例:DRV/r+2NRTIs组76.1%(191/251),DTG+DRV/r组85.7%(215/251),DTG+TDF/XTC组81.6%(231/283)。
  • 与DRV/r+2NRTIs相比,DTG+DRV/r的抑制率差异为9.6%(95%CI 2.7-16.4),DTG+TDF/XTC为9.0%(95%CI 1.4-16.6)。
  • DTG+TDF/XTC组病毒学失败者中3/27(13%)检出中高水平多替拉韦耐药,DTG+DRV/r组未检出。
  • 未观察到达芦那韦耐药。

临床怎么用

  • 对于一线NNRTI方案失败的HIV-1感染者,可优先考虑含多替拉韦的二线方案。
  • 使用DTG+TDF/XTC方案时需警惕多替拉韦耐药的发生,并加强耐药监测。

局限性

  • 研究在资源有限地区开展,结果外推需谨慎。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longer-term outcome data following second-line antiretroviral therapy initiation in resource-limited settings is limited, especially in regions where genotypic resistance is inaccessible. This analysis evaluated extended efficacy and tolerability data from the D2EFT study. METHODS: D2EFT is a completed, multicenter, phase IIIB/IV, randomized, open-label trial in 14 low- and middle-income countries. People with human immunodeficiency virus (HIV) who had failed first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens were switched to 1 of ritonavir-boosted darunavir plus 2 nucleoside reverse transcriptase inhibitors (DRV/r + 2NRTIs), ritonavir-boosted darunavir plus dolutegravir (DTG + DRV/r), or dolutegravir with tenofovir disoproxil fumarate plus either lamivudine or emtricitabine (DTG + TDF/XTC), with or without pre-switch genotyping. Here we report virological suppression at 96 weeks, defined as HIV RNA <50 copies/mL in a modified intention-to-treat population. RESULTS: Between November 2017 and January 2022, 1190 participants were screened, 828 were randomized, and 826 were included in the analysis. At week 96, the proportions of participants with HIV RNA <50 copies/mL were 191/251 (76.1%) in DRV/r + 2NRTIs, 215/251 (85.7%) in DTG + DRV/r, and 231/283 (81.6%) in DTG + TDF/XTC. The treatment differences (95% confidence intervals [CIs]) in proportions achieving virological suppression were 9.6% (2.7, 16.4) in DTG + DRV/r and 9.0% (1.4, 16.6) in DTG + TDF/XTC, compared to DRV/r + 2NRTIs. Intermediate or high-level dolutegravir resistance was identified in 3/27 (13%) of virological failures in individuals taking DTG + TDF/XTC but in no one taking DTG + DRV/r. No darunavir resistance was observed. CONCLUSIONS: After 96 weeks of follow-up, DTG + DRV/r and DTG + TDF/XTC demonstrated virological superiority over DRV/r + 2NRTIs after first-line NNRTI-failure. However, emerging dolutegravir resistance, which was observed only in individuals taking DTG + TDF/XTC, requires ongoing global surveillance.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nyein PP, Borok M, Eriobu N, et al. A Randomized Trial to Compare Dolutegravir Plus Boosted Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in People With HIV-1, Whose First-line Non-nucleoside Reverse Transcriptase Inhibitor Therapy Has Failed: Final 96-week Results of the D2EFT Study. Clin Infect Dis. 2026. PMID: 40577173. doi:10.1093/cid/ciaf346

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。